Appetite stimulants use in cystic fibrosis
- PMID: 18219690
- DOI: 10.1002/ppul.20766
Appetite stimulants use in cystic fibrosis
Abstract
Cystic fibrosis (CF) is an autosomal recessive disease. It affects multiple body organs. The lungs and pancreas are the most affected which results in progressive lung damage and pancreatic insufficiency. Due to the disease process, CF patients require significantly higher caloric intake than recommended for other individuals. The nutritional goal for CF patients is to achieve normal growth and development and, once genetic potential is reached, to maintain good nutritional status throughout life. Evidence has shown that lung function is closely associated with nutritional status in CF and that nutritional status is an independent predictor of survival. Most CF patients are on a high calorie diet to help achieve normal growth and development and maintain good lung function. Inadequate caloric intake in CF can lead to malnutrition. Malnutrition in CF requires careful, multidisciplinary history taking, physical exam, and overall patient/family assessment. Only by determining the actual cause of the malnutrition can appropriate and safe therapies be used to treat it. Appetite stimulants, although efficacious in treating malnutrition in CF, should only be prescribed if decreased food intake secondary to inadequate appetite is the principal cause of the malnutrition and all other contributing factors have been assessed, ruled-out or treated. In this review, we attempted to summarize the use of several appetite stimulants used in CF and other diseases to improve appetite and maximize caloric intake.
(c) 2008 Wiley-Liss, Inc.
Similar articles
-
Nutrition in cystic fibrosis.Semin Respir Crit Care Med. 2009 Oct;30(5):579-86. doi: 10.1055/s-0029-1238916. Epub 2009 Sep 16. Semin Respir Crit Care Med. 2009. PMID: 19760545 Review.
-
Pathogenesis of malnutrition in cystic fibrosis, and its treatment.Clin Nutr. 2000 Dec;19(6):387-94. doi: 10.1054/clnu.1999.0079. Clin Nutr. 2000. PMID: 11104588 Review.
-
Cyproheptadine is an effective appetite stimulant in cystic fibrosis.Pediatr Pulmonol. 2004 Aug;38(2):129-34. doi: 10.1002/ppul.20043. Pediatr Pulmonol. 2004. PMID: 15211696 Clinical Trial.
-
Growth assessment of paediatric patients with CF comparing different auxologic indicators: A multicentre Italian study.J Pediatr Gastroenterol Nutr. 2009 Sep;49(3):335-42. doi: 10.1097/MPG.0b013e31818f0a39. J Pediatr Gastroenterol Nutr. 2009. PMID: 19543116
-
Evaluation of body mass index percentiles for assessment of malnutrition in children with cystic fibrosis.Eur J Clin Nutr. 2007 Jun;61(6):759-68. doi: 10.1038/sj.ejcn.1602582. Epub 2007 Jan 10. Eur J Clin Nutr. 2007. PMID: 17213872
Cited by
-
Inactivation of FOXA2 by Respiratory Bacterial Pathogens and Dysregulation of Pulmonary Mucus Homeostasis.Front Immunol. 2020 Mar 25;11:515. doi: 10.3389/fimmu.2020.00515. eCollection 2020. Front Immunol. 2020. PMID: 32269574 Free PMC article. Review.
-
Altered de novo lipogenesis contributes to low adipose stores in cystic fibrosis mice.Am J Physiol Gastrointest Liver Physiol. 2012 Aug 15;303(4):G507-18. doi: 10.1152/ajpgi.00451.2011. Epub 2012 Jun 7. Am J Physiol Gastrointest Liver Physiol. 2012. PMID: 22679004 Free PMC article.
-
Nutritional outcomes following gastrostomy in children with cystic fibrosis.Pediatr Pulmonol. 2012 Aug;47(8):743-8. doi: 10.1002/ppul.22507. Epub 2012 Feb 1. Pediatr Pulmonol. 2012. PMID: 22298389 Free PMC article.
-
Growth failure and treatment in cystic fibrosis.J Cyst Fibros. 2019 Oct;18 Suppl 2(Suppl 2):S82-S87. doi: 10.1016/j.jcf.2019.08.010. J Cyst Fibros. 2019. PMID: 31679733 Free PMC article. Review.
-
Oxandrolone Improves Height Velocity and BMI in Patients with Cystic Fibrosis.Int J Pediatr Endocrinol. 2009;2009:826895. doi: 10.1155/2009/826895. Epub 2010 Jan 24. Int J Pediatr Endocrinol. 2009. PMID: 20145725 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical